No.6
Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population
Participants in the uproleselan arm had a median overall survival of 13 months vs. 12.3 months in the placebo arm.
返信
投資の参考になりましたか？
